Literature DB >> 8337734

Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.

L M Galvao1, R M Nunes, J R Cançado, Z Brener, A U Krettli.   

Abstract

A complement-mediated lysis test (CoML) using living trypomastigotes was compared with conventional serological methods and with haemoculture. Over a 10 years follow-up period evidence was obtained which supported the view that chagasic patients, treated with nitroheterocyclic drugs, in whom CoML had reverted to negative, might be considered cured despite conventional serology remaining positive.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337734     DOI: 10.1016/0035-9203(93)90501-g

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  32 in total

1.  Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients.

Authors:  Wendell S F Meira; Lúcia M C Galvão; Eliane D Gontijo; George L L Machado-Coelho; Karen A Norris; Egler Chiari
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

3.  Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease.

Authors:  S A Laucella; E L Segura; A Riarte; E S Sosa
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

4.  Why does GM1 induce a potent beneficial response to experimental Chagas disease?

Authors:  S Cossy Isasi; C A Condat; G J Sibona
Journal:  HFSP J       Date:  2009-01-21

5.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Montserrat Gállego; Paulo Luis López-Chejade; Julio A Urbina; Joaquim Gascón
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

6.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

Review 7.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

8.  Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.

Authors:  Olindo Assis Martins-Filho; Silvana Maria Eloi-Santos; Andréa Teixeira Carvalho; Rodrigo Corrêa Oliveira; Anis Rassi; Alejandro Ostemayer Luquetti; Gustavo Gabriel Rassi; Zigman Brener
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 9.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

10.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.